Study reports luteolin and glycitein ameliorate age-related locomotor decline in C. elegans

Researchers have demonstrated that the Codonopsis pilosula-derived compounds luteolin and glycitein mitigate locomotor decline and sarcopenia in C. elegans via DAF-16-dependent pathways, showing divergent dependencies on autophagic processes.

A study published in Biogerontology reports that luteolin and glycitein, two bioactive compounds isolated from the traditional medicinal herb Codonopsis pilosula, significantly ameliorate the deterioration of body bend and thrashing frequencies in aged C. elegans.

Both compounds were shown to mitigate age-associated sarcopenia by reducing abnormalities in muscle structure and mitochondrial morphology.

The researchers established that the beneficial effects of both compounds on locomotion depend on the transcription factor DAF-16/FOXO, as both promote DAF-16 nuclear translocation and their effects are abolished upon daf-16 knockdown.

The mechanisms of the two compounds diverge regarding autophagy: luteolin-mediated locomotor improvement requires an lgg-1-dependent autophagic process, whereas glycitein exerts its effects independently of autophagy.

In contrast, a third isolated compound, α-spinasterol, did not improve locomotor capacity despite altering autophagosome levels.

Sarcopenia and functional motor decline represent major biomedical challenges in aging populations, and validating safe, naturally derived compounds targets these endpoints directly.

The study reinforces the role of the DAF-16/FOXO pathway as a central hub for healthspan modulation, demonstrating its direct involvement in maintaining structural muscle integrity.

The finding that functional muscle preservation can be achieved through both autophagy-dependent and autophagy-independent pathways offers multiple distinct downstream drug targets for structural and functional preservation.

The identification of distinct autophagic requirements for luteolin versus glycitein supports the screening and development of highly targeted, mechanistically differentiated candidates for sarcopenia and muscle aging.

These findings provide further scientific rationale for developers of healthy-aging therapeutics to explore the therapeutic separation of FOXO activation and autophagy induction.

Preclinical studies evaluating whether the DAF-16/FOXO-mediated muscle-preservation effects of luteolin and glycitein translate to mammalian models of age-related sarcopenia.